Jazz Pharmaceuticals (JAZZ) Long-Term Deferred Tax (2016 - 2025)
Jazz Pharmaceuticals has reported Long-Term Deferred Tax over the past 14 years, most recently at $869.1 million for Q4 2025.
- Quarterly Long-Term Deferred Tax rose 55.13% to $869.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $869.1 million through Dec 2025, up 55.13% year-over-year, with the annual reading at $869.1 million for FY2025, 55.13% up from the prior year.
- Long-Term Deferred Tax was $869.1 million for Q4 2025 at Jazz Pharmaceuticals, up from $846.2 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $869.1 million in Q4 2025 and troughed at $258.5 million in Q1 2021.
- The 5-year median for Long-Term Deferred Tax is $447.2 million (2023), against an average of $468.4 million.
- Biggest five-year swings in Long-Term Deferred Tax: rose 0.1% in 2022 and later surged 55.13% in 2025.
- Tracing JAZZ's Long-Term Deferred Tax over 5 years: stood at $311.1 million in 2021, then grew by 20.94% to $376.2 million in 2022, then rose by 27.0% to $477.8 million in 2023, then rose by 17.25% to $560.2 million in 2024, then soared by 55.13% to $869.1 million in 2025.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods came in at $869.1 million, $846.2 million, and $602.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.